Shang Luo Shi

Researchers are investigating the effectiveness and safety of ursodeoxycholic acid in treating gastric intestinal metaplasia in adults aged 18 to 75 years who do not have Helicobacter pylori infection. The study aims to find out if ursodeoxycholic acid can help reverse this condition compared to a placebo. This is a Phase 4, multicenter, randomized, placebo-controlled trial focusing on patients with specific stages of gastric intestinal metaplasia diagnosed within the last 3 months. Participants will take either ursodeoxycholic acid or a placebo capsule, each 250mg, three times daily for 6 months. They will visit the hospital every 4 weeks for symptom evaluation and to receive their medication supply. The treatment period lasts 6 months with regular monitoring to assess the impact of the drug. Throughout the study, participants will have clinic visits every 4 weeks for checkups and tests to track their symptoms and medication adherence. Researchers will measure the regression and progression rates of gastric intestinal metaplasia based on OLGIM stages from enrollment until the end of treatment at 6 months. Safety and any medical problems experienced during treatment will also be closely monitored.